Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

19 June 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Zofran Articles

UK FIRMS BOOSTED BY YEAR-END US APPROVALS

4 January 1993

SMITHKLINE BEECHAM ON TRACK

21 December 1992

ONDANSETRON LINKED TO CARDIAC ARREST

9 November 1992

EUROPE STOCK COMMENT

7 September 1992

GLAXO PROSPECTS GLOOM: FACT OR FICTION?

3 August 1992

SCHERING-PLOUGH IN UK CANCER DRUG DEAL

6 July 1992

Anti-emetics in chemotherapy

15 June 1992

STOCK MARKET COMMENTARY: EUROPE

18 May 1992

ZOFRAN APPROVED IN UK FOR PONV

11 May 1992

POST-ELECTION OUTLOOK FOR UK HEALTH SECTOR

20 April 1992

COMPARATIVE STUDY CALL WITH ZOFRAN

23 March 1992

FRANCE PROBES GLAXO'S IMIGRAN PROMOTION

23 March 1992

NEW CHEMICAL ENTITIES UPDATE FOR 1991

10 February 1992

ALZHEIMER'S DISEASE: A GROWING BURDEN

20 January 1992

GLAXO INCREASES CNS EMPHASIS IN USA

13 January 1992

Showing 101-115 of 115 articles

Go to beginningPrevious
  • 1
  • 2
NextGo to end
  • Hot Topics
  • Most Read
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
  • Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
  • Additional indications in Japan for Roche's Avastin and Astellas' Prograf
  • Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
  • Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
  • Additional indications in Japan for Roche's Avastin and Astellas' Prograf
  • Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS